Where does Indivior Pharmaceuticals, Inc. 's cash flow data come from?

Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	$251M+20.1%	$209M+63.3%	$128M+18.5%	$108M+1,643%	-$7M-200%
Depreciation and amortization	$9M-10.0%	$10M-23.1%	$13M-7.1%	$14M0.0%	$14M-12.5%
Stock-based compensation	$29M+11.5%	$26M-3.7%	$27M+3.8%	$26M+8.3%	$24M0.0%
Net cash from operating activities	-$111M-311%	-$27M—	——	——	——
Capital expenditures	$81M+22.7%	$66M+13.8%	$58M+28.9%	$45M+40.6%	$32M+10.3%
Acquisitions, net of cash acquired	——	$0—	$0—	$0—	$0—
Net cash from investing activities	-$80M-21.2%	-$66M-94.1%	-$34M-262%	$21M-46.2%	$39M-43.5%
Repurchases of common stock	——	——	——	——	$148M-14.5%
Proceeds from issuance of debt	——	——	——	——	$249M-25.0%
Repayments of debt	$346M+1,935%	$17M-93.2%	$250M+1.2%	$247M+1.6%	$243M+1.3%
Net cash from financing activities	-$6M+80.0%	-$30M—	——	——	——
Net increase (decrease) in cash	-$197M-58.9%	-$124M-178%	$159M-22.8%	$206M+66.1%	$124M+4,033%
Free cash flow	-$192M-106%	-$93M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Indivior Pharmaceuticals, Inc. 's cash flow data come from?: Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.